Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $1.03 EPS, FY2027 earnings at $2.78 EPS, FY2028 earnings at $3.85 EPS and FY2029 earnings at $4.74 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Other equities research analysts have also issued reports about the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

Shares of TGTX opened at $35.19 on Friday. TG Therapeutics has a 12 month low of $12.93 and a 12 month high of $37.58. The business’s fifty day simple moving average is $30.92 and its two-hundred day simple moving average is $28.38. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market cap of $5.48 billion, a price-to-earnings ratio of -351.86 and a beta of 2.30.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the business. Arizona State Retirement System boosted its stake in TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock worth $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 463 shares during the last quarter. Private Advisor Group LLC grew its stake in TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 542 shares in the last quarter. Finally, Brookstone Capital Management grew its stake in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 624 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.